Despite recent advancements in immuno-oncology, not all patients with cancer benefit from current treatments, and additional therapeutic options are needed for both hematologic malignancies and solid tumors.1

Cytotoxic T-cells play an important role in identifying and eliminating cancer cells;2 however, cancer cells can develop mechanisms to evade T-cell recognition and destruction.1 Bispecific T-cell engager (BiTE®) technology engages the patient’s T-cells to directly target cancer cells to engage and attack cancer cells that may have previously learned to evade or escape these mechanisms. BiTE® molecules are engineered from two flexibly linked, single-chain antibodies—one that is specific for a selected tumor-antigen and the other that is specific for CD3 found on T-cells.2,3

Learn more about the BiTE® immuno-oncology platform and the goal of enhancing cancer treatment in a video presented by Amgen.

References

  1. Alatrash G, Jakher H, Stafford PD, et al. Expert Opin Drug Saf. 2013;12:631-45.
  2. Baeuerle PA, Kufer P, Bargou R. Curr Opin Mol Ther. 2009;11:22-30.
  3. Yuraszeck T, Kasichayanula S, Benjamin JE. Clin Pharmacol Ther. 2017;101:634-45.